Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

Michael O'Riordan

December 23, 2025

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Todd Neale

October 02, 2024

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

FDA Clears SAPIEN 3 With Alterra Prestent for Pulmonary Valve Replacement

L.A. McKeown

December 20, 2021

News Daily News

European Regulators Approve First Transcatheter MV Replacement Device

Michael O'Riordan

January 30, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

L.A. McKeown

May 06, 2019

News Daily News

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

Yael L. Maxwell

December 05, 2018

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

FDA Approves Sapien M3 for Transseptal Mitral Valve Replacement

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

FDA Approves TriClip TEER Device for Tricuspid Repair

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Most Patient-Reported Outcome Measures in CVD Fall Short

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

FDA Clears SAPIEN 3 With Alterra Prestent for Pulmonary Valve Replacement

European Regulators Approve First Transcatheter MV Replacement Device

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Vici Venous Stent Receives FDA Approval for Iliofemoral Obstructive Disease

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content